India's Synmedic and Basis-Metigreens to launch production of antiviral generics in Russia

Russian drugmaker Basis-Metigreens together with the India’s Synmedic company plan to launch the production of an analogue of Ingavirin (pentandioici imidazolylaethanamidum), one of the most popular antiviral drugs in Russia, which is produced by the local Valenta Pharm, The Pharma Letter’s local correspondent reports.

The timing of production is not specified, while permission for clinical trials of the drug has already been received until the end of 2024. Sales of Ingavirin this year exceeded 5 billion roubles ($55 million) in Russia, while the original product is protected by a number of patents in the Russian Federation and the Eurasian Economic Space.

General Director of Basis-Metigreens Sergei Khodor said in an interview with the Russian Kommersant business paper, under the terms of the project, the company will act as owner and customer of the technology, while the Indian firm will be responsible for the production of the drug. Valenta Pharm, which owns the rights for the original product, declined to comment.